October 5, 2017
Payer Rep Shoji Kono Drug prices should not be raised even if they prove to have quite a good cost-effective profile through an envisioned “cost-effective assessment (CEA)” scheme, a vocal health ministry panel member representing bill payers stressed on October...read more